CD47 and acute myeloid leukemia: Clinical trials for novel targeted agents and immunotherapeutic approaches such as TP53MUT re-activators and anti-CD47 blockade have shown potential in the frontline setting of TP53MUT AML and should be explored further in this high-risk population [40].